How Quickly Must SIRVA Symptoms Begin After Vaccination?
Updated: Aug 13
The traditional 48-hour definition is important—but the published literature is more complicated than a single cutoff suggests.
One of the most important questions in evaluating suspected Shoulder Injury Related to Vaccine Administration (SIRVA) is deceptively simple:
How soon after vaccination must shoulder symptoms begin?
The frequently cited answer is within 48 hours. That is well supported by the historical and medicolegal definitions of SIRVA and by much of the clinical literature. However, a review of the broader evidence shows an important distinction:
48 hours is a strong defining feature of classic SIRVA, but it is not the onset window used by every research study or every publication describing post-vaccination shoulder pathology.
That distinction matters clinically and in medical-legal causation analysis.
Key Takeaways
Classic SIRVA is characterized by rapid onset, generally during the first 24–48 hours after vaccination.
Large datasets support this pattern: in one chart-confirmed population study, 93.5% of 371 cases developed symptoms within two days.
In a 1,220-report VAERS analysis following influenza vaccination, 70.7% reported symptom onset on the day of vaccination.
However, investigators have used broader research definitions ranging from 7 days to 2 weeks, and some COVID-19 adhesive capsulitis series report mean onset around 8–12 days.
Therefore, onset after 48 hours should not necessarily be treated as biologically impossible, but the longer the interval, the more carefully alternative explanations and the specific proposed mechanism should be evaluated.
Where Did the 48-Hour Rule Come From?
The concept of SIRVA emerged from reports of patients developing persistent shoulder pain and loss of motion following vaccination. The original literature emphasized an unusually close temporal relationship between injection and symptoms.
That concept subsequently became incorporated into formal medicolegal definitions.
The U.S. Vaccine Injury Compensation Program (VICP) definition described by Zheng and colleagues requires pain to occur within 48 hours of vaccination, involve the vaccinated shoulder, occur without prior shoulder pain or dysfunction that would explain the condition, and lack another condition that better explains the symptoms.
Australian criteria summarized in the literature similarly emphasize onset within 24–48 hours, together with restricted motion, pain with movement, suspected incorrect administration technique, and imaging abnormalities.
Thus, the 48-hour threshold is not arbitrary. Rapid symptom onset is embedded in the historical concept of SIRVA.
What Do Large Clinical Datasets Actually Show?
The most useful evidence comes from larger cohorts rather than isolated case reports.
Zheng et al.
Zheng and colleagues developed and validated an electronic health record method for identifying shoulder conditions following vaccination. For research purposes, they intentionally used a broader definition than the VICP definition: symptoms could begin within 7 days rather than 48 hours.
That creates an informative natural experiment: if the definition allowed seven days, when did the cases actually begin?
The answer was striking:
347 of 371 cases (93.5%) developed symptoms within two days of vaccination.
Only:
24 of 371 (6.5%) developed symptoms between days 3 and 7.
This is one of the strongest pieces of evidence regarding timing because the study did not force every patient into a 48-hour window, yet the overwhelming majority still developed symptoms within that interval.
Hibbs et al.
Hibbs and colleagues reviewed 1,220 reports of atypical shoulder pain and dysfunction following inactivated influenza vaccination.
Among these reports:
863 of 1,220 (70.7%) described symptoms beginning on the day of vaccination.
This reinforces the predominance of very early onset.
However, VAERS data have important limitations. Reports are spontaneous, clinical information may be incomplete, and the database cannot establish that vaccination caused the reported condition. The authors specifically cautioned against interpreting the reports as confirmed incident vaccine-caused shoulder injuries.
The study is therefore informative about the reported temporal pattern, but not definitive proof of causation.
Australian Registry Data Also Support Rapid Onset
The Australian SAEFVIC experience provides another large clinical dataset.
Marshall and colleagues followed 102 SIRVA cases reported between 2007 and 2020. The study used a clinical framework emphasizing rapid pain, pain with movement, restricted range of motion, and absence of another preexisting shoulder injury or infection.
Importantly, the study found that the timing of symptom onset did not significantly predict whether symptoms ultimately resolved. Among 85 patients successfully followed for at least six months, 86% experienced complete resolution.
A subsequent Australian COVID-19 SIRVA series by Petrakis and colleagues again characterized SIRVA as protracted shoulder pain and restricted movement beginning within the first 48 hours after vaccination.
The median reported onset in that cohort was measured in hours rather than days, although onset varied with age and sex.
Taken together, these registry studies are consistent with rapid onset as the predominant clinical pattern.
Why, Then, Do Some Studies Use 7 Days or Even 2 Weeks?
This is where the literature becomes more complicated. There is no universally applied research definition of SIRVA.
Different investigators have broadened the onset window for different purposes.
Zheng, 7 days
As discussed above, Zheng et al. defined a research case as beginning within seven days.
Yet 93.5% of the ultimately confirmed cases still began within two days.
Bass et al., 2 weeks
A COVID-19 study by Bass and colleagues used an even broader definition. They included persistent unilateral shoulder symptoms that first occurred within two weeks of ipsilateral deltoid COVID-19 vaccination and did not resolve within 48 hours.
That definition is useful for identifying a broad spectrum of potentially vaccine-associated shoulder conditions, but it should not be confused with the narrower traditional SIRVA definition.
The distinction between case ascertainment for research and criteria supporting individual medical causation is important.
Adhesive Capsulitis Presents a Particular Timing Problem
The greatest challenge to a strict 48-hour interpretation comes from the post-COVID-19 adhesive capsulitis literature.
Mülkoğlu and colleagues evaluated 21 patients who developed adhesive capsulitis after COVID-19 vaccination. Their mean interval between vaccination and symptom onset was:
8.0 ± 6.4 days. The same paper discussed a nine-patient series by Ghosh and colleagues in which the mean onset was: 12.3 ± 3.1 days.
Other publications in our SIRVA evidence database likewise use broader onset windows for post-vaccination adhesive capsulitis.
This creates an important scientific question: Are these later-onset cases the same biological entity as classic immediate-onset SIRVA?
The available literature does not definitively answer that question. Some authors classify them as SIRVA. Others acknowledge that their timing falls outside traditional criteria.
That uncertainty should be preserved rather than resolved simply by changing the definition.
The Mechanism Matters When Evaluating Timing
Not all proposed SIRVA mechanisms necessarily imply the same onset pattern.
Direct mechanical injury
If a needle directly penetrates or traumatizes:
a rotator cuff tendon,
bursa,
capsule,
periosteum, or
another pain-sensitive structure
immediate or very rapid pain would be biologically intuitive. This pattern is frequently described in individual case reports.
Inflammatory response
SIRVA has also been proposed to result from vaccine antigen being inadvertently introduced into synovial or periarticular structures, producing a local inflammatory or immunologic response.
The literature describes this mechanism as unintended injection into structures adjacent to or deep to the deltoid, followed by inflammatory or immune activation. Such a mechanism could theoretically produce a somewhat less immediate presentation than direct needle trauma.
But the existence of a biologically conceivable delayed inflammatory response does not establish that any shoulder condition appearing days or weeks later was caused by vaccination. The longer the latency, the greater the opportunity for coincidental shoulder disease or another cause to intervene.
What About Individual Case Reports?
The individual-patient literature reinforces the heterogeneity but also demonstrates how frequently classic cases begin immediately.
But the literature also contains reports beginning several days, and occasionally weeks, after vaccination. Those later cases should be interpreted differently from the classic immediate-onset phenotype rather than simply pooled together as though the temporal evidence were equivalent.
A Useful Way to Think About Timing
For clinical and medical-legal review, I find it more useful to treat timing as a continuum of evidentiary support rather than as a binary switch.
Symptom onset | Relationship to classic SIRVA literature |
During injection / immediate | Strongly characteristic |
Within 24 hours | Strongly characteristic |
24–48 hours | Consistent with traditional definition |
3–7 days | Reported, but less typical |
8–14 days | Included in some studies; outside classic criteria |
Several weeks later | Weak temporal fit for classic SIRVA; requires particularly careful alternative-cause analysis |
This is not a validated diagnostic scoring system. It is a practical way of expressing what the published evidence shows: the distribution is heavily concentrated toward early onset, while progressively later presentations are less representative of the classic syndrome.
Does Missing the 48-Hour Window Automatically Exclude SIRVA?
From a strict VICP-style definitional standpoint, onset beyond 48 hours may fail the applicable definition.
From a broader medical and scientific standpoint, the answer is more nuanced.
Published researchers have studied shoulder conditions beginning within seven days, two weeks, and, in some case series, even longer.
Therefore, it would be inaccurate to state that the medical literature contains no potentially vaccine-associated shoulder presentations after 48 hours.
It would be equally inaccurate, however, to conclude that timing is unimportant.
The larger datasets point strongly toward early onset as the dominant pattern.
Why Timing Alone Cannot Establish Causation
Consider two hypothetical cases.
A patient with no prior shoulder symptoms experiences sharp pain during vaccination, develops restricted motion that evening, and is subsequently found to have pathology anatomically corresponding to the injection region.
Compare that with a patient who is asymptomatic for three weeks after vaccination and then gradually develops shoulder stiffness.
Both may have a temporal sequence of:
vaccination → shoulder symptoms.
But the strength of the temporal evidence is not equivalent.
That does not mean the first case is necessarily caused by vaccination or the second necessarily is not. It means the causation analysis should account for the strength, or weakness, of the temporal relationship.
Timing Should Be Evaluated With the Rest of the Evidence
A high-quality SIRVA causation analysis should consider timing alongside:
Prior shoulder symptoms
Prior shoulder imaging
Injection location
Needle depth and technique
Immediate injection symptoms
Anatomical plausibility
Physical examination
MRI and ultrasound findings
Alternative diagnoses
Subsequent trauma
Clinical course
Response to treatment
The importance of this approach is illustrated by the large VAERS study. Hibbs and colleagues explicitly cautioned that their data could neither establish that the reports represented vaccine-caused injuries nor exclude the possibility that some represented new or aggravated shoulder injuries related to improper administration.
That is an appropriate way to interpret much of the SIRVA literature.
What Does the Evidence Support?
The current evidence supports several conclusions.
First, rapid onset is one of the most reproducible features of classic SIRVA. The traditional definition centers on symptoms beginning within 48 hours, and the larger observational datasets strongly support that pattern.
Second, the 48-hour threshold is partly definitional. Studies using broader surveillance or research definitions have captured patients with later symptom onset.
Third, later-onset cases exist in the literature. This is particularly evident in some COVID-19 adhesive capsulitis series, where mean onset has been reported around 8–12 days.
Fourth, later onset does not carry the same temporal weight as immediate onset. In the 371-case Zheng cohort, only 6.5% of confirmed cases began between days 3 and 7, compared with 93.5% within the first two days.
And finally, timing should inform causation rather than substitute for it.
The Bottom Line
So, how quickly must SIRVA symptoms begin?
For classic SIRVA, the best-supported answer remains:
Within 48 hours of vaccination.
That interval is supported by traditional definitions, medicolegal criteria, registry studies, large surveillance datasets, population-based research, and many individual case reports.
But the medical literature is not completely binary. Some investigators have used broader windows, and later-onset shoulder disorders, particularly adhesive capsulitis, have been reported following vaccination.
References:
Atanasoff S, Ryan T, Lightfoot R, Johann-Liang R. Shoulder injury related to vaccine administration (SIRVA). Vaccine. 2010;28(51):8049-8052.
Zheng C, Duffy J, Liu ILA, Sy LS, Navarro RA, Kim SS, Ryan DS, Chen W, Qian L, Mercado C, Jacobsen SJ. Identifying cases of Shoulder Injury Related to Vaccine Administration (SIRVA) in the United States: development and validation of a natural language processing method. JMIR Public Health Surveill. 2022;8(5):e30426.
Zheng C, Duffy J, Liu IA, Sy LS, Chen W, Qian L, et al. Risk for shoulder conditions after vaccination: a population-based study using real-world data. Ann Intern Med. 2022;175(5):634-643.
Hibbs BF, Ng CS, Museru O, Moro PL, Marquez P, Woo EJ, Cano MV, Shimabukuro TT. Reports of atypical shoulder pain and dysfunction following inactivated influenza vaccine, Vaccine Adverse Event Reporting System (VAERS), 2010-2017. Vaccine. 2020;38(5):1137-1143.
Marshall T, Addison M, Crawford NW, Buttery JP, Cheng DR. Aiming too high: Shoulder injury related to vaccine administration (SIRVA): a case series. Vaccine. 2022;40(52):7505-7509.
Petrakis N, Addison M, Penak B, Schrader S, Mallard J, Clothier HJ, Buttery JP, Crawford NW, Cheng DR. Shoulder injury following COVID-19 vaccine administration: a case series and proposed diagnostic algorithm. Expert Rev Vaccines. 2023;22(1):299-306.
Bass JR, Poland GA. Shoulder injury related to vaccine administration (SIRVA) after COVID-19 vaccination. Vaccine. 2022;40(34):4964-4971.
Mülkoğlu C, Tiftik T, Deniz AB, Taka İ, Genç H. Analysis of patients with adhesive capsulitis after COVID-19 vaccination: an observational study. Turk J Phys Med Rehabil. 2023;69(4):520-525.
Ghosh S, Pandey SK, Biswas A, Pandey J. Adhesive capsulitis after COVID-19 vaccination: a case series. Am J Phys Med Rehabil. 2023;102(6):e79-e82.
Sussman WI, Davitt K, Mitchell K, Sussman J, Latzka E. Sonographic features of Shoulder Injury Related to Vaccine Administration (SIRVA) and treatment with tenotomy and ultrasound-guided vacuum aspiration: a case series. Clin J Sport Med. 2026. Published online ahead of print.
Bodor M, Montalvo E. Vaccination-related shoulder dysfunction. Vaccine. 2007;25(4):585-587.
Martín Arias LH, Sanz Fadrique R, Sáinz Gil M, Salgueiro-Vazquez ME. Risk of bursitis and other injuries and dysfunctions of the shoulder following vaccinations. Vaccine. 2017;35(37):4870-4876.
Hesse EM, Atanasoff S, Hibbs BF, et al. Shoulder Injury Related to Vaccine Administration (SIRVA): petitioner claims to the National Vaccine Injury Compensation Program, 2010-2016. Vaccine. 2020;38(5):1076-1083.
About the Author
Walter I. Sussman, DO, FAAPM&R is a board-certified Sports Medicine and Physical Medicine & Rehabilitation physician.
This article is intended for educational purposes and does not constitute a medical opinion regarding any individual case. Assessment of diagnosis and causation requires review of the specific medical history, records, imaging, and circumstances involved.
Comments